High reputation Octreotide Acetate - Desmopressin acetate for injection – JYMed

Product Detail

Product Tags

Related Video

Feedback (2)

We not only will try our greatest to offer you excellent services to each individual client, but also are ready to receive any suggestion offered by our buyers for Degarelix Acetate Gmp Provider, Lanreotide Acetate Gmp Supplier, C46h65n13o12s2, our products have good reputation from the world as its most competive price and our most advantage of after-sale service to the clients。
High reputation Octreotide Acetate - Desmopressin acetate for injection – JYMed Detail:

1ml:4μg / 1ml:15μg   Strength

Indication:

INDICATIONS AND USAGE

Hemophilia A: Desmopress in Acetate Injection 4 mcg/mL is indicated for patients with hemophilia A with factor VIII coagulant activity levels greater than 5%.

Desmopress in acetate injection will often maintain hemostasis in patients with hemophilia A during surgical procedures and postoperatively when administered 30 minutes prior to scheduled procedure.

Desmopress in acetate injection will also stop bleeding in hemophilia A patients with episodes of spontaneous or trauma-induced injuries such as hemarthroses, intramuscular hematomas or mucosal bleeding.

Desmopress in acetate injection is not indicated for the treatment of hemophilia A with factor VIII coagulant activity levels equal to or less than 5%, or for the treatment of hemophilia B, or in patients who have factor VIII antibodies.

In certain clinical situations, it may be justified to try desmopress in acetate injection in patients with factor VIII levels between 2% to 5%; however, these patients should be carefully monitored. von Willebrand’s Disease (Type I): Desmopres s in acetate injection 4 mcg/mL is indicated for patients with mild to moderate classic von Willebrand’s disease (Type I) with factor VIII levels greater than 5%. Desmopress in acetate injection will often maintain hemostasis in patients with mild to moderate von Willebrand’s disease during surgical procedures and postoperatively when administered 30 minutes prior to the scheduled procedure.

Desmopress in acetate injection will usually stop bleeding in mild to moderate von Willebrand’s patients with episodes of spontaneous or trauma-induced injuries such as hemarthroses, intramuscular hematomas or mucosal bleeding.

Those von Willebrand’s disease patients who are least likely to respond are those with severe homozygous von Willebrand’s disease with factor VIII coagulant activity and factor VIII von

Willebrand factor antigen levels less than 1%. Other patients may respond in a variable fashion depending on the type of molecular defect they have. Bleeding time and factor VIII coagulant activity, ristocetin cofactor activity, and von Willebrand factor antigen should be checked during administration of desmopress in acetate injection to ensure that adequate levels are being achieved.

Desmopress in acetate injection is not indicated for the treatment of severe classic von Willebrand’s disease (Type I) and when there is evidence of an abnormal molecular form of factor VIII antigen.

Diabetes Insipidus: Desmopress in acetate injection 4 mcg/mL is indicated as antidiuretic replacement therapy in the management of central (cranial) diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region.

Desmopress in acetate injection is ineffective for the treatment of nephrogenic diabetes insipidus.

Desmopress in acetate is also available as an intranasal preparation. However, this means of delivery can be compromised by a variety of factors that can make nasal insufflation ineffective or inappropriate.

These include poor intranasal absorption, nasal congestion and blockage, nasal discharge, atrophy of nasal mucosa, and severe atrophic rhinitis. Intranasal delivery may be inappropriate where there is an impaired level of consciousness. In addition, cranial surgical procedures, such as transsphenoidal hypophysectomy, create situations where an alternative route of administration is needed as in cases of nasal packing or recovery from surgery.

CONTRAINDICATIONS

Desmopress in acetate injection 4 mcg/mL is contraindicated in individuals with known hypersensitivity to desmopress in acetate or to any of the components of desmopress in acetate injection 4 mcg/mL.

Desmopress in acetate injection is contraindicated in patients with moderate to severe renal impairment (defined as a creatinine clearance below 50ml/min).

Desmopress in acetate injection is contraindicated in patients with hyponatremia or a history of hyponatremia.


Product detail pictures:

High reputation Octreotide Acetate - Desmopressin acetate for injection – JYMed detail pictures


Related Product Guide:
After Valsartan Recalls, Regulators Grapple with Nitrosamine Contamination in APIs | Synthetic Angiotensin Ii Gmp Provider From China
全球抗肿瘤药物市场概览【3】-姜广策的博客-要么第一要么唯一!-搜狐博客 | Trelstar(Triptorelin Pamoate)

carry on to further improve, to guarantee merchandise high-quality in line with market and buyer standard necessities. Our organization has a top quality assurance procedure have already been established for High reputation Octreotide Acetate - Desmopressin acetate for injection – JYMed, The product will supply to all over the world, such as: Madrid, Thailand, Johor, We will do our utmost to cooperate & satisfied with you relying on top-grade quality and competitive price and best after service ,sincerely look forward to cooperating with you and make achievements in the future!
  • This is a honest and trustworthy company, technology and equipment are very advanced and the prodduct is very adequate, there is no worry in the suppliment.
    5 Stars By Jerry from Florida - 2016.02.18 15:54
    Company director has very rich management experience and strict attitude, sales staff are warm and cheerful, technical staff are professional and responsible,so we have no worry about product,a nice manufacturer.
    5 Stars By Salome from Japan - 2015.12.05 13:53

    Related Products

    WhatsApp Online Chat !